Evidence map›Paper›PMID 41847681›Full record

ArticleIJTLD open2026

J G Pasipanodya, L Nqwata, J Schmitz, S Srivastava, C N Wanjalla, R S Wallis, K E Dooley

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

J G PasipanodyaDivision of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA.
L NqwataDivision of Pulmonology, Department of Internal Medicine, University of Witwatersrand, Johannesburg, South Africa.
J SchmitzDivision of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA.
S SrivastavaDivision of Infectious Diseases, Department of Medicine, School of Medicine at University of Texas at Tyler, Tyler, Texas, USA.
C N WanjallaDivision of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA.
R S WallisDivision of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA.
K E DooleyDivision of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA.

Funding

Mentoring Investigators in HIV and Tuberculosis Therapeutics ResearchK24AI150349 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DOOLEY, KELLY E. · 2020 to 2025
$789k
NIAID NIH HHS K24 AI150349
6 · The paper itself

Abstract

backgroundLack of quantitative and reproducible treatment response biomarkers is slowing the development of better therapy regimens for pulmonary

methodsWe retrospectively compared serial sputum culture (SSC) trajectories and outcomes of 29 P-MAC patients, of whom 26/29 (90%) had concurrent HIV infection, treated with guideline-based therapy (GBT) versus non-GBT regimens at a tertiary hospital in Gauteng province of South Africa between 2013 and 2017. We used 'current value' parameterisation of joint models with BERSs as longitudinal biomarkers for the composite outcomes of time-to-death or therapy failure.

resultsOverall, initial bacterial burden and BERS trajectories were heterogeneous. BERSs ranged from -0.034 to 0.013 log

conclusionBERSs from sputum are potential P-MAC treatment response biomarkers, which should be evaluated further in larger prospective studies of people with and without HIV.

Indexed as

all-cause mortality outcomesbacterial eliminationnon-TB mycobacteriaSouth Africa

Identifiers

PMID41847681
PMCPMC12991566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.